Key Takeaways
- More than 240 mRNA therapeutic programmes are in active clinical development globally as of Q1 2026, a 68% increase on the 2023 figure, with oncology accounting for roughly 44% of that pipeline.
- Personalised mRNA cancer vaccines have produced objective response rates above 50% in early melanoma and non-small-cell lung cancer trials when combined with checkpoint inhibitors, driving a wave of Phase III commitments from large-cap pharma.
- The rare disease segment is attracting particular investor attention: six mRNA programmes targeting metabolic and hepatic disorders have entered Phase II or III since January 2025, with combined disclosed funding exceeding $4.2 billion.
- Manufacturing cost-per-dose for mRNA therapeutics has fallen by an estimated 60% since 2021, making commercial viability a near-term prospect for indications beyond infectious disease for the first time.
When Moderna and BioNTech demonstrated that lipid nanoparticle-delivered mRNA could generate protective immunity in tens of millions of people within months of a novel pathogen's emergence, the scientific community absorbed the proof of concept quickly. The commercial community took a little longer. By 2025, however, investment in non-COVID mRNA programmes had surpassed COVID-related R&D spending for the first time, according to an analysis of disclosed financing rounds across 87 companies. The question is no longer whether mRNA works outside the vaccine context. The question is which therapeutic categories will see the first billion-dollar product, and on what timeline.
Oncology Leads the Pipeline, Personalised Vaccines Are the Bet
Personalised cancer vaccines represent the most closely watched segment in the entire mRNA pipeline. The underlying logic is compelling: sequence a patient's tumour, identify neoantigens specific to that malignancy, design a bespoke mRNA construct encoding up to 34 of those antigens, and administer it alongside a PD-1 inhibitor. Phase II data from programmes in melanoma have shown 18-month recurrence-free survival rates of 78% in the mRNA-plus-checkpoint arm versus 62% in the checkpoint-only arm, across trial populations of 150 to 200 patients. Those numbers have been sufficient to trigger Phase III initiations by at least three major pharmaceutical groups in the first quarter of 2026 alone, with combined enrolment targets exceeding 3,000 patients.
Solid tumours beyond melanoma are increasingly in scope. Non-small-cell lung cancer, bladder cancer, and head-and-neck squamous cell carcinoma have all generated early signals from mRNA vaccine candidates in 2025 and early 2026. The manufacturing challenge is substantial: producing a patient-specific construct within a clinically useful turnaround time currently averages 28 to 35 days, and programmes aiming for commercial scale are targeting 18 days or fewer. Three dedicated mRNA personalised medicine manufacturing facilities opened in Europe and North America between mid-2025 and the first quarter of 2026, with combined annual capacity for roughly 12,000 individual patient doses.
Rare Disease: A Slower Road, but the Commercial Logic Is Compelling
The rare disease application of mRNA is structurally different from oncology. Rather than encoding tumour antigens, programmes in this category use mRNA to instruct the body to produce a functional protein that a genetic defect prevents it from making. Propionic acidaemia, methylmalonic acidaemia, and ornithine transcarbamylase deficiency are among the metabolic disorders with active Phase II or III programmes as of Q1 2026. The liver's natural affinity for lipid nanoparticles makes hepatic conditions particularly amenable to the technology, and the head-to-head pharmacokinetic profile against enzyme replacement therapy has been favourable in two of the three most advanced programmes. Orphan drug designation in both the US and EU has been granted to four of the six most advanced candidates.
Pricing power in rare disease is structurally higher than in infectious disease, which is a key reason institutional investors are paying close attention. The chief medical officer of a mid-cap European biotech focused on metabolic disorders noted in a January 2026 investor briefing that annual treatment costs for comparable enzyme replacement therapies range from $250,000 to $500,000 per patient. An mRNA alternative with a comparable efficacy and safety profile, delivered quarterly rather than bi-weekly, would command a significant premium. Two companies in this space have filed for Breakthrough Therapy designation in the US, with decisions expected in the second half of 2026.
"The infrastructure built for COVID mRNA production has essentially handed the industry a 10-year manufacturing head start. We would have spent the better part of a decade building out the lipid nanoparticle formulation and fill-finish capacity that now sits idle or underutilised at multiple sites. The question for regulators is how quickly they adapt their frameworks to reflect what is now a well-characterised platform, rather than treating each new mRNA programme as if the delivery technology were novel."
Chief Regulatory Officer at a large European pharmaceutical group (industry survey respondent)
Infectious Disease Beyond COVID: RSV, Influenza, and the Combination Opportunity
The third major growth vector is infectious disease outside of COVID-19. RSV mRNA vaccines for older adults and for maternal immunisation have both produced Phase III efficacy data in the 80% to 85% range, directly competitive with protein subunit approaches approved in 2023 and 2024. The commercial stakes are meaningful: the global RSV vaccine market is projected to reach $8.5 billion by 2029, and mRNA entrants are expected to capture between 25% and 35% of that figure based on current pipeline timelines.
Combination vaccines represent a longer-term but structurally important opportunity. The ability to encode antigens for multiple pathogens within a single mRNA construct enables a seasonal respiratory combination product targeting influenza A, influenza B, RSV, and SARS-CoV-2 variants within a single annual dose. Two such combination programmes entered Phase I trials in late 2025. If immunogenicity data are favourable, Phase II initiation is expected by early 2027. The simplification benefit for national immunisation programmes is significant, and health technology assessment bodies in the UK, Germany, and France have each indicated willingness to engage on combination vaccine submissions ahead of formal filing.
- Oncology (near-term, 2026 to 2028): Personalised neoantigen vaccines in melanoma and NSCLC are the most mature programmes. Phase III data readouts from at least two major trials are expected before the end of 2027, with potential first approvals in the US following shortly thereafter.
- Rare disease (medium-term, 2027 to 2030): Metabolic and hepatic disorders with high unmet need and established orphan drug pathways offer the clearest commercial route. Manufacturing scalability at small patient volumes is well suited to the current cost structure.
- Infectious disease combinations (longer-term, 2028 and beyond): Combination respiratory vaccines depend on multi-antigen immunogenicity data still being generated. Regulatory precedent for combination mRNA products does not yet exist in any major jurisdiction, adding at least 12 to 18 months to approval timelines.
The strategic implication for large-cap pharmaceutical groups is straightforward: the window for licensing or acquiring best-in-class mRNA platform companies is narrowing. Several of the most advanced private programmes in personalised oncology and rare disease are now valued above $2 billion on the strength of clinical data alone, compared with sub-$500 million valuations for comparable-stage assets in 2022. For companies that did not build or acquire mRNA capabilities during the COVID infrastructure boom, the cost of entry is rising. The next 24 months will likely determine which organisations are positioned as platform leaders and which are left negotiating licensing terms on commercially mature technology.
